Binding molecule specific for lrig-1 protein and use thereof
AssigneeGood T Cells, Inc.
InventorsJung Ho KIM, Beom Seok KIM
Life of this patent
Estimating the term…
Abstract
The present invention relates to a binding molecule capable of specifically binding to Lrig-1 protein, which is on the surface of regulatory T cells. The binding molecule provided in the present invention can suppress the function of regulatory T cells to effectively prevent, ameliorate, or treat cancer, particularly solid tumor. The binding molecule has advantages of more effectively targeting the Lrig-1 protein as compared with antibodies against Lrig-1 which are previously commercially available, and also possessing very good binding capacity thereto.
Claims21
A binding molecule which specifically binds to Lrig-1 (leucine-rich and immunoglobulin-like domains 1) protein, the binding molecule comprising:
- a heavy chain variable region that contains a heavy chain CDR1 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 5, 13, 21, and 29;
- a heavy chain CDR2 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 6, 14, 22, and 30;
- a heavy chain CDR3 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 7, 15, 23, and 31;
- and
- a light chain variable region that contains a light chain CDR1 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 8, 16, 24, and 32;
- a light chain CDR2 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 9, 17, 25, and 33;
- a light chain CDR3 consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:
- 10, 18, 26, and 34.
2-3. (canceled)
18-21. (canceled)
Dependencies are inferred from the claim text.